151 related articles for article (PubMed ID: 38373940)
1. The effect of a treatment switch to integrase Strand transfer inhibitor-based regimens on weight gain and other metabolic syndrome-related conditions.
Maman O; Ahmad WA; Perzon O; Mahlab-Guri K; Elbirt D; Elinav H
BMC Infect Dis; 2024 Feb; 24(1):221. PubMed ID: 38373940
[TBL] [Abstract][Full Text] [Related]
2. Real-world weight changes in people with HIV-1 at risk of weight gain (female, Black or Hispanic) switching from integrase strand transfer inhibitors.
Donga P; Emond B; Shah A; Bookhart BK; Anderson D; Vermette-Laforme M; Rossi C; Lafeuille MH
J Comp Eff Res; 2023 Jan; 12(1):e220147. PubMed ID: 36445208
[No Abstract] [Full Text] [Related]
3. Contribution of integrase inhibitor use, body mass index, physical activity and caloric intake to weight gain in people living with HIV.
Guaraldi G; Milic J; Bacchi E; Carli F; Menozzi M; Franconi I; Raimondi A; Ciusa G; Masi V; Belli M; Guaraldi S; Aprile E; Mancini M; Mussini C; Lake JE; Erlandson KM
HIV Res Clin Pract; 2022 Nov; 24(1):1-6. PubMed ID: 36883678
[No Abstract] [Full Text] [Related]
4. Mitochondrial DNA haplogroups and weight gain following switch to integrase strand transfer inhibitor-based antiretroviral therapy.
Erlandson KM; Wu K; Lake JE; Samuels DC; Bares SH; Tassiopoulos K; Koethe JR; Brown TT; Leonard M; Benson CA; Haas DW; Hulgan T;
AIDS; 2021 Mar; 35(3):439-445. PubMed ID: 33252493
[TBL] [Abstract][Full Text] [Related]
5. Weight change with integrase strand transfer inhibitors among virally suppressed Thai people living with HIV.
Han WM; Kerr SJ; Avihingsanon A; Boettiger DC
J Antimicrob Chemother; 2022 Nov; 77(12):3242-3247. PubMed ID: 36101517
[TBL] [Abstract][Full Text] [Related]
6. Weight gain following switch to integrase inhibitors from non-nucleoside reverse transcriptase or protease inhibitors in people living with HIV in the United States: analyses of electronic medical records and prescription claims.
Tse J; Prajapati G; Zhao X; Near AM; Kumar PN
Curr Med Res Opin; 2023 Sep; 39(9):1237-1246. PubMed ID: 37480288
[TBL] [Abstract][Full Text] [Related]
7. Incidence of cardiometabolic outcomes among people living with HIV-1 initiated on integrase strand transfer inhibitor versus non-integrase strand transfer inhibitor antiretroviral therapies: a retrospective analysis of insurance claims in the United States.
Rebeiro PF; Emond B; Rossi C; Bookhart BK; Shah A; Caron-Lapointe G; Lafeuille MH; Donga P
J Int AIDS Soc; 2023 Jun; 26(6):e26123. PubMed ID: 37306118
[TBL] [Abstract][Full Text] [Related]
8. Brief Report: Weight Gain in Persons With HIV Switched From Efavirenz-Based to Integrase Strand Transfer Inhibitor-Based Regimens.
Norwood J; Turner M; Bofill C; Rebeiro P; Shepherd B; Bebawy S; Hulgan T; Raffanti S; Haas DW; Sterling TR; Koethe JR
J Acquir Immune Defic Syndr; 2017 Dec; 76(5):527-531. PubMed ID: 28825943
[TBL] [Abstract][Full Text] [Related]
9. Comparison of weight gain after antiretroviral switch to integrase strand transfer inhibitor or tenofovir alafenamide-based therapy.
Sjaarda A; Bernstein A; Sparks A; Saber S; Siegel M
Infection; 2022 Apr; 50(2):407-412. PubMed ID: 34449049
[TBL] [Abstract][Full Text] [Related]
10. Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada.
Bourgi K; Jenkins CA; Rebeiro PF; Palella F; Moore RD; Altoff KN; Gill J; Rabkin CS; Gange SJ; Horberg MA; Margolick J; Li J; Wong C; Willig A; Lima VD; Crane H; Thorne J; Silverberg M; Kirk G; Mathews WC; Sterling TR; Lake J; Koethe JR;
J Int AIDS Soc; 2020 Apr; 23(4):e25484. PubMed ID: 32294337
[TBL] [Abstract][Full Text] [Related]
11. Relationship between weight gain and insulin resistance in people living with HIV switching to integrase strand transfer inhibitors-based regimens.
Milic J; Renzetti S; Ferrari D; Barbieri S; Menozzi M; Carli F; Dolci G; Ciusa G; Mussini C; Calza S; Guaraldi G
AIDS; 2022 Oct; 36(12):1643-1653. PubMed ID: 35727163
[TBL] [Abstract][Full Text] [Related]
12. Weight Change When Initiating, Switching to, and Discontinuing Integrase Strand Transfer Inhibitors in People Living with HIV.
Tieosapjaroen W; Chow EPF; Fairley CK; Hoy J; Aguirre I; Ong JJ
AIDS Patient Care STDS; 2023 Mar; 37(3):131-137. PubMed ID: 36809049
[TBL] [Abstract][Full Text] [Related]
13. Weight Gain Associated With Integrase Stand Transfer Inhibitor Use in Women.
Kerchberger AM; Sheth AN; Angert CD; Mehta CC; Summers NA; Ofotokun I; Gustafson D; Weiser SD; Sharma A; Adimora AA; French AL; Augenbraun M; Cocohoba J; Kassaye S; Bolivar H; Govindarajulu U; Konkle-Parker D; Golub ET; Lahiri CD
Clin Infect Dis; 2020 Jul; 71(3):593-600. PubMed ID: 31504324
[TBL] [Abstract][Full Text] [Related]
14. Greater Weight Gain in Treatment-naive Persons Starting Dolutegravir-based Antiretroviral Therapy.
Bourgi K; Rebeiro PF; Turner M; Castilho JL; Hulgan T; Raffanti SP; Koethe JR; Sterling TR
Clin Infect Dis; 2020 Mar; 70(7):1267-1274. PubMed ID: 31100116
[TBL] [Abstract][Full Text] [Related]
15. Weight gain before and after switch from TDF to TAF in a U.S. cohort study.
Mallon PW; Brunet L; Hsu RK; Fusco JS; Mounzer KC; Prajapati G; Beyer AP; Wohlfeiler MB; Fusco GP
J Int AIDS Soc; 2021 Apr; 24(4):e25702. PubMed ID: 33838004
[TBL] [Abstract][Full Text] [Related]
16. Real-World Assessment of Weight Change in African American Females and Hispanics with HIV-1 After Initiating Integrase Strand-Transfer Inhibitors or Protease Inhibitors.
Chen YW; Anderson D; Pericone CD; Donga P
J Health Econ Outcomes Res; 2022; 9(1):1-10. PubMed ID: 35083364
[No Abstract] [Full Text] [Related]
17. Integrase Strand Transfer Inhibitor Start or Switch Impacts Learning in Women With HIV.
O'Halloran JA; Wang K; Spence AB; Williams DW; Dastgheyb R; Fitzgerald KC; Kamkwalala AR; Maki PM; Sharma A; Gustafson DR; Milam J; Weber KM; Adimora AA; Ofotokun I; Fischl MA; Konkle-Parker D; Lahiri CD; Sheth AN; Xu Y; Rubin LH
J Acquir Immune Defic Syndr; 2021 Apr; 86(5):593-599. PubMed ID: 33394812
[TBL] [Abstract][Full Text] [Related]
18. Weight gain after antiretroviral therapy initiation in people living with HIV in the United States: analyses of electronic medical records and prescription claims.
Zhao X; Prajapati G; Tse J; Near AM; Kumar PN
Curr Med Res Opin; 2023 Jul; 39(7):997-1006. PubMed ID: 37334707
[TBL] [Abstract][Full Text] [Related]
19. Real-World Assessment of Weight Change in People with HIV-1 After Initiating Integrase Strand Transfer Inhibitors or Protease Inhibitors.
Chen YW; Hardy H; Pericone CD; Chow W
J Health Econ Outcomes Res; 2020; 7(2):102-110. PubMed ID: 32766375
[TBL] [Abstract][Full Text] [Related]
20. Energy balance and body composition after switch between integrase strand transfer inhibitors and doravirine among people with HIV.
Erlandson KM; Mohaweche R; Morrow M; Mawhinney S; Khuu V; Boyd M; Balasubramanyam A; Melanson EL; Lake JE
J Antimicrob Chemother; 2024 Jan; 79(1):179-185. PubMed ID: 38000089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
